contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
    id
  }
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}


remedy-vanguard-relaunch-included-estimates

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Analytiker

Atte Riikola

Remedy Entertainment är en spelutvecklare. Verksamheten är främst inriktad mot utveckling av actionspel, med särskilt fokus på 3D-teknik. Exempel på spel som bolaget utvecklat inkluderar ett flertal olika versioner av Alan Wake, Max Payne, samt Control. Remedy utvecklar också sin egen spelmotor och verktygsteknologi som driver många av spelen. Bolaget grundades år 1995 och har sitt huvudkontor i Esbo.

Här är analytikern @Atte_Riikola:s kommentarer om de senaste nyheterna från det här intressanta finska spelföretaget.  Remedy announced on Thursday a strategic partnership agreement with Annapurna Pictures for Control 2. Remedy will self-publish the game, but Annapurna will fund 50% of the game and have the rights to extend the Control and Alan Wake brands into film and television. In our projections, we had assumed that Remedy would fund Control 2 entirely on its own and raise additional funds to do so. The current agreement is more balanced from a risk perspective and eliminates the need for additional funding that we had anticipated. At the same time, the deal offers good royalty potential and a low-risk opportunity to reach new audiences through movies and TV series. Overall, we view the deal as good for Remedy and will update our forecasts accordingly in the near future.                   Inderes              Remedy finds good strategic partner for Control 2 - Inderes    Remedy announced on Thursday a strategic partnership agreement with Annapurna Pictures for Control 2. Remedy will self-publish the game, but Annapurna will fund 50% of the game and have the rights to extend the Control and Alan Wake brands into...

Inför Q1 från Remedy på måndag.                    Inderes              Remedy Q1 on Monday: Our forecast sees AW2 royalties only starting to show in...    Remedy will report its Q1 results on Monday at 9.00 am EEST. We will review the report afresh in Remedy earnings live starting at 8.55 am (in Finnish). We still expect a very weak quarter in terms of numbers before AW2 starts to generate royalties in...

Remedy Q4 onsdag: AW2-royalties och publiceringskontrakt för Control-spel medför fluktuationer i 2024 års siffror.                    Inderes              Remedy Q4 next Wednesday: AW2 royalties and Control games' publishing...    Remedy will report its Q4 results next Wednesday at 9.00 am EET. With the profit warning issued in February, the earnings figures that are clearly in the red as expected are already known.                             Remedy will report its Q4 results next Wednesday at 9.00 am EET. With the profit warning issued in February, the earnings figures that are clearly in the red as expected are already known. In addition, the company already provided information on the sales development of Alan Wake 2, so key short-term information concerning the figures has already been given. This year, royalties from Alan Wake 2 should clearly support the company’s growth and earnings performance, and the main interest in the report is the outlook for the current year. However, the ongoing negotiations on a possible new publishing contract with Control 2 and Condor bring its own variable to the equation. Remedy acquired all rights to the Control game brand from 505 Games at the end of February at a good price in our opinion.

BREAKING NEWS FROM REMEDY!!!                    Inderes              Remedy acquires full rights to the Control franchise from 505 Games at a good...    We see the agreement as very positive for Remedy's long-term potential, as the company is now in a strong position to decide to self-publish future Control games and/or to negotiate with a new publishing partner to finance projects on better terms.

Här är en färsk analys av Remedy.                    Inderes              Remedy: AW2 sales figures fell short of our overly optimistic expectations -...    Friday's sales figures for Alan Wake 2 show that the game is off to a good start and is Remedy's fastest selling game to date. However, following very positive critical reviews, we expected an even faster start and have now revised our overly...                             Friday’s sales figures for Alan Wake 2 show that the game is off to a good start and is Remedy’s fastest selling game to date. However, following very positive critical reviews, we expected an even faster start and have now revised our overly optimistic forecasts downwards.

Remedyn aktiekurs har sjunkit mycket, delvis av en anledning, men kanske till och med för mycket.  Hur som helst, detta företag har skapat fantastiska spel, som Alan Wake. Jag gillar Inderes analyser eftersom de är ärliga. De är till exempel inte alltför tjuriga.                   Inderes              Remedy: Back in the game - Inderes    The investor sentiment around Remedy has recently soured, where we believe the key factors are the write-down of Vanguard’s development expenditure and the postponement of the financial statements based on publishing contract negotiations. In...                             The investor sentiment around Remedy has recently soured, where we believe the key factors are the write-down of Vanguard’s development expenditure and the postponement of the financial statements based on publishing contract negotiations. In addition, uncertainty about Alan Wake 2’s commercial success causes uncertainty around the stock. We believe that the content of the publishing contract and the sales figures of AW2 will be clarified in connection with the financial statements (3/20) at the latest, and with the decreased valuation we feel Remedy’s long-term potential looks interesting again.

Remedy reports its Q4 results, and here are the analyst’s comments related to it.                    Inderes              Remedy Q4 on Friday: Outlook and Alan Wake 2 sales performance in focus  -...    Remedy will report its Q4 results on Friday at 9.00 am EET. 2023 is still a clear investment phase for Remedy. This is reflected in the Q4 and full-year results, which are clearly negative.                             Remedy will report its Q4 results on Friday at 9.00 am EET. 2023 is still a clear investment phase for Remedy. This is reflected in the Q4 and full-year results, which are clearly negative. This year, royalties from Alan Wake 2 should clearly support the company’s growth and earnings performance, and the main interest in the report is the outlook for the current year and information/commentary on the sales performance of AW2. In the big picture, the progress of the game projects in development in the production pipeline will again be key this year, as with the ramp-up of the multi-project model, we estimate that the release of AW2 is just the starting point for many more game releases to come this decade.

Remedy Entertainment

We have updated our estimates to include the reboot of the Vanguard project under the codename Kestrel. As a result, cash flows from Remedy’s projects will focus slightly more at the end of this decade.

<p>We have updated our estimates to include the reboot of the Vanguard project under the codename Kestrel. As a result, cash flows from Remedy’s projects will focus slightly more at the end of this decade. Overall, Remedy’s share valuation prices good success for future games, which we believe is also justified in light of AW2’s excellent reception. The positive momentum around AW2 is also a clear driver supporting the share in the short term. As a whole, the risk/return ratio is now too thin in the neutral scenario in line with our estimates, although the hit game option associated with each game project can change the situation quickly. </p> 

	2022	23e	24e
Omsättning	43,6	31,5	70,1
tillväxt-%	−2,54 %	−27,65 %	122,40 %
EBIT (adj.)	−0,6	−20,6	17,6
EBIT-%	−1,29 %	−65,17 %	25,14 %
EPS (adj.)	−0,13	−1,22	1,04
Utdelning	0,10	0,10	0,10
Direktavkastning	0,46 %	0,57 %	0,57 %
P/E (just.)	-	-	16,71
EV/EBITDA	126,51	-	8,90

Remedy: Vanguard relaunch included in estimates

Remedy Entertainment

Key Estimate Figures2023-11-15